Advertisement
ALNY vs REGN
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Regeneron Pharmaceuticals (REGN) Stock Comparison
Key Takeaways
- ALNY focuses on RNAi therapeutics for rare diseases like ATTR amyloidosis, with recent partnerships boosting its pipeline but facing short-term share weakness and YTD declines of around 20%.
- REGN leverages blockbuster drugs like EYLEA and Dupixent for broader indications in eye, immunology, and emerging obesity treatments, supported by a larger market cap of $80B versus ALNY's $42B.
- Recent market activity shows both stocks under pressure in the past month, with ALNY down ~3% weekly and REGN down ~6%, amid biotech sector volatility.
- ALNY exhibits stronger 1-year returns (~30%) compared to REGN (~14%), highlighting differing momentum in relative performance.
- Pipeline catalysts include ALNY's cardiovascular deals and REGN's obesity trial successes, influencing investor sentiment.
- Tickeron's AI tools reveal patterns favoring stability in diversified biotech plays like REGN amid current conditions.
Introduction
This stock comparison examines ALNY and REGN, two leaders in biotechnology with innovative pipelines in RNAi and monoclonal antibodies. ALNY specializes in gene-silencing therapies for rare genetic diseases, while REGN targets prevalent conditions like eye disorders and immunology. Traders seeking momentum in niche RNAi advancements or investors eyeing diversified revenue from blockbusters like Dupixent and EYLEA will find value in analyzing their relative performance, recent developments, and market positioning in the evolving biotech landscape.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) pioneers RNAi therapeutics, offering treatments like ONPATTRO and AMVUTTRA for hereditary ATTR amyloidosis, alongside GIVLAARI and OXLUMO for other rare disorders. In recent market activity, ALNY shares have traded around $315, within a 52-week range of $206-$496, reflecting volatility. The stock has declined about 20% YTD and shown modest 1-month gains of ~1%, pressured by analyst downgrades and broader biotech sentiment. Key influences include a major collaboration with Tenaya Therapeutics for cardiovascular targets, positive trial completions like KARDIA-3 for hypertension, and ongoing expansions in ATTR cardiomyopathy approvals. These developments sustain pipeline optimism, though near-term profitability concerns and insider sales have tempered enthusiasm.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) develops biologics for eye diseases, inflammation, and oncology, with flagships EYLEA (for macular degeneration) and Dupixent (co-marketed with Sanofi for atopic dermatitis and asthma). Trading near $757 in a 52-week range of $476-$821, REGN has slipped ~2% YTD and ~6% over the past month, lagging amid sector headwinds. Sentiment drivers encompass positive Phase 3 obesity data for olatorepatide, Dupixent label expansions into COPD and urticaria, and EYLEA HD uptake offsetting legacy competition. Strong collaboration revenues from Dupixent profits bolster stability, though EYLEA transition risks and R&D investments weigh on short-term momentum.
Trending AI Robots
Tickeron’s Trending AI Robots page features over 25 top-performing AI trading bots curated from more than 350 available on the platform, which collectively trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like AI/ML pattern recognition, technical and fundamental analysis, and hedging, tailored to current market volatility in sectors such as semiconductors, energy, and biotech. Standout stats include annualized returns up to +208%, win rates reaching 94.92%, profit factors as high as 4.96, and profit-to-drawdown ratios exceeding 22. Virtual and brokerage agents offer risk management with no minimums for signals, averaging 60-90% win rates on select portfolios of 1-25 tickers. Explore these high-conviction options to enhance your trading edge in dynamic conditions.
Head-to-Head Comparison
ALNY and REGN diverge in business models: ALNY's RNAi platform targets rare diseases with high unmet need but narrower markets, while REGN's antibody focus yields broader exposure via EYLEA/Dupixent, generating superior cash flows. Growth drivers contrast ALNY's pipeline catalysts like zilebesiran partnerships against REGN's obesity and immunology expansions. Recent momentum favors ALNY's 30% 1-year gain over REGN's 14%, yet REGN offers lower beta (0.40) and reduced risk from diversification. Sector exposure ties both to biotech volatility, with ALNY facing execution risks in novel tech and REGN biosimilar pressures; sentiment leans toward REGN's profitability.
Tickeron AI Verdict
Tickeron’s AI currently favors REGN due to its trend consistency from Dupixent growth, superior stability via larger scale and cash reserves, and stronger relative positioning amid biotech uncertainty. While ALNY shows pipeline promise, REGN's catalysts like obesity data offer higher probability of near-term upside in observable metrics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and REGN is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- REGN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 2 TA indicator(s) are bullish while REGN’s TA Score has 6 bullish TA indicator(s).
- ALNY’s TA Score: 2 bullish, 5 bearish.
- REGN’s TA Score: 6 bullish, 3 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -1.49% price change this week, while REGN (@Biotechnology) price change was +0.60% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.20%. For the same industry, the average monthly price growth was -1.14%, and the average quarterly price growth was +2120.55%.
Reported Earning Dates
ALNY is expected to report earnings on Jul 30, 2026.
REGN is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (+1.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ALNY | REGN | ALNY / REGN | |
| Capitalization | 38.4B | 64.5B | 60% |
| EBITDA | 866M | 5.75B | 15% |
| Gain YTD | -27.625 | -20.111 | 137% |
| P/E Ratio | 72.31 | 15.01 | 482% |
| Revenue | 4.29B | 14.9B | 29% |
| Total Cash | 3.01B | 8.75B | 34% |
| Total Debt | 1.27B | 2.71B | 47% |
ALNY | REGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 59 | 88 | |
SMR RATING 1..100 | 13 | 60 | |
PRICE GROWTH RATING 1..100 | 72 | 63 | |
P/E GROWTH RATING 1..100 | 100 | 41 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (2) in the Biotechnology industry is significantly better than the same rating for ALNY (90). This means that REGN’s stock grew significantly faster than ALNY’s over the last 12 months.
ALNY's Profit vs Risk Rating (59) in the Biotechnology industry is in the same range as REGN (88). This means that ALNY’s stock grew similarly to REGN’s over the last 12 months.
ALNY's SMR Rating (13) in the Biotechnology industry is somewhat better than the same rating for REGN (60). This means that ALNY’s stock grew somewhat faster than REGN’s over the last 12 months.
REGN's Price Growth Rating (63) in the Biotechnology industry is in the same range as ALNY (72). This means that REGN’s stock grew similarly to ALNY’s over the last 12 months.
REGN's P/E Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for ALNY (100). This means that REGN’s stock grew somewhat faster than ALNY’s over the last 12 months.
| ALNY | REGN | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 67% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 65% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 70% | 2 days ago 62% |
| Advances ODDS (%) | 13 days ago 75% | 2 days ago 63% |
| Declines ODDS (%) | 5 days ago 67% | 16 days ago 54% |
| BollingerBands ODDS (%) | 2 days ago 67% | 2 days ago 66% |
| Aroon ODDS (%) | 2 days ago 74% | 2 days ago 63% |
Advertisement